Having completed their phase 1b clinical trial in psoriasis, with outstanding results, SFA Therapeutics, Inc. is now positioning itself for the commercial development of SFA-002D, a drug that has the potential to reset the immune system. This drug has shown significant results in the treatment of psoriasis, as a proof of concept for application of the platform in multiple autoimmune diseases. SFA Therapeutics is pleased to announce the following organizational changes.